Jivi® (antihemophilic factor (recombinant), PEGylated-aucl) – New drug approval
August 30, 2018 - Bayer announced the FDA approval of Jivi [antihemophilic factor (recombinant), PEGylated-aucl], for use in previously treated adults and adolescents (12 years of age and older) with hemophilia A (congenital Factor VIII deficiency) for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes.
Top